Idera Pharmaceuticals $IDRA reported that its ongoing Phase 1 study on intra-tumoral IMO-2125 in combination with Ipilimumab in patients with PD-1 refractory metastatic melanoma showed good clinical results. IMO-2125 in combination with Ipilimumab has been well tolerated at all 3 dose levels studied to date.